85 results
Experience and lessons learned from Ghana's immunization program.
The table shows the awarded price per dose (in US$) per product per supplier per calendar year, based on a multi year supply agreement.
VIEW-hub is an open-access data visualization tool that displays data on vaccine introduction, use, coverage, access, impact, and disease burden for nine vaccines, including the rotavirus vaccine.
This rotavirus-focused brief covers the economic costs of rotavirus disease and the value of vaccines.
ROTA provides scientific and technical evidence to scientific authorities such as policymakers on rotavirus disease and vaccines.
In accordance with its mandate to provide guidance to Member States on health policy matters, WHO publishes vaccine position papers providing global vaccine and immunization recommendations for...
COSTVAC is an Excel-based toolkit that provides structured guidance on how to estimate the cost of routine immunization from a sample of health facilities and administrative levels of the health...
The WHO website provides a list of certain diseases for which vaccines are available, and a list of some pathogens for which vaccines and/or monoclonal antibodies (mAbs) are in development. For each...
In 2020, Ghana's switched from ROTARIX to ROTAVAC in its routine immunization program in order to save money and cold chain space. An economic analysis of this switch, conducted by PATH, the...
UNIVAC is a single universal vaccine impact and cost-effectiveness decision support model with a standardized, accessible Excel-based (now based in R), interface and a familiar set of input steps and...
The Consortium aims to deliver a more sustainable, efficent, and transparent approach to generating disease burden and vaccine impact estimates. It works on aggregating the estimates across a...
Il s’agit d’un outil simple dans Excel qui permet d’évaluer et de comparer les coûts des programmes de vaccination antirotavirus pour chaque vaccin antirotavirus disponible sur le marché...
Remplacer un vaccin par un autre peut impacter significativement le budget national alloué à la vaccination. Pour le programme palestinien de vaccination contre le rotavirus, ce choix s’est...
La vaccination antirotavirus en Palestine a considérablement fait diminuer la charge de morbidité que représente la diarrhée chez les enfants, et ses bénéfices ont été renforcés par un...
Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced...
Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced...
Current live, oral rotavirus vaccines (LORVs) are reducing severe diarrhea in all settings, but they are not as effective in places with the highest burden. Alternative approaches in advanced...
Rotavirus vaccination in Palestine has significantly reduced the burden of diarrhea among children, and the benefits were sustained through a vaccine product switch.
In 2018, the Palestinian...
Middle-income countries not eligible for support from Gavi, the Vaccine Alliance, have been slow to introduce rotavirus vaccines, largely due to cost concerns. A PATH analysis shows that, in most...
Middle-income countries (MICs) that are not eligible for funding from Gavi, the Vaccine Alliance, have been slow to adopt rotavirus vaccines. Few studies have evaluated the cost-effectiveness and...
Switching from one vaccine product to another can have a significant impact on a country’s budget. For Palestine’s rotavirus vaccination program, a switch paid off.
This brief describes an...
PATH’s Rotavirus Vaccine Cost Calculator is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs annually and for a period of 10 years with each rotavirus...
This manual explains the most common procedures for rotavirus strain surveillance. Section 1 presents brief overviews of the methods and discusses implementation • issues. Sections 2-4 describe ...
This document provides background data regarding safety concerns of rotavirus vaccines and presents guidelines for routine post-marketing surveillance to assess the safety of rotavirus vaccines, with...
This information bulletin addresses the implications and required guidance associated with the upcoming scheduled shift in vaccine vial monitor (VVM) of the GlaxoSmithKline Biologicals SA (GSK)...
This generic protocol outlines a uniform approach to monitoring the impact of rotavirus vaccines that can be modified by countries to meet their specific needs. It provides background and...
This product fact sheet is intended for use by global and regional vaccine policy makers. The product fact sheet provides information on Rota procured by V3P reporting countries, including analyses...
Live oral rotavirus (RV) vaccines used worldwide are most effective in reducing diarrheal hospitalizations from RV in high income countries and least effective in low income countries where RV...
Background: Diarrheal disease is one of the leading causes of illness and death in young children in the world, especially the developing countries. Diarrheal disease results in about half a million...
Background: Strategies are needed to improve oral rotavirus vaccine (RV), which provides sub-optimal protection in developing countries. Probiotics and zinc supplementation could improve RV...
Background: Rotavirus is a highly contagious virus causing gastroenteritis, mostly in children under the age of 5. Since 2006, two vaccines are available in Germany. In 2013, these were included into...
Rotavirus is a leading cause of severe pediatric diarrhea globally, estimated to have caused 120,000 deaths among
children aged <5 years in sub-Saharan Africa in 2013 (1). In 2009, the World Health...
Rotavirus is the most common cause of moderate-to-severe infant diarrhoea in developing countries, resulting in enormous morbidity, mortality, and economic burden. A bovine-human reassortant...
Diarrhea is still one of the main killers in developing countries. Rotavirus is the main agent that causes severe gastroenteritis. It can very quickly lead to fatal dehydration, especially among very...
Background: Each year, rotavirus gastroenteritis is responsible for about 37% of deaths from diarrhea among children younger than 5 years of age worldwide, with a disproportionate effect in...
The 9th African rotavirus symposium was held in Maputo, Mozambique from the 8th to 10th of December 2015, including a total of 101 delegates from 17 countries, 15 of which were African countries....
IVAC is releasing a set of tools capturing and synthesizing the latest and best available data around rotavirus diseases and vaccines with technical decision-makers in mind. We have developed a...
The global analysis, entitled Gap Analysis of Rotavirus Vaccine Impact Evaluations in Settings of Routine Use, is the output of an IVAC-maintained database of completed and ongoing vaccine impact...
Rotavirus is a major cause of severe gastroenteritis among very young children. In developing countries, rotavirus is the major cause of mortality in children under five years old, causing up to 20%...
Rotavirus infection, which can be prevented by vaccination, is responsible for a high burden of acute gastroenteritis disease in children, especially in low-income countries. An appropriate...
Introduction of infant oral rotavirus vaccination in the UK in July 2013 has resulted in decreased hospitalisations and Emergency Department (ED) visits for acute gastroenteritis (AGE), for both...
Background
The test-negative design (TND), an epidemiologic method currently used to measure rotavirus vaccine (RV) effectiveness, compares the vaccination status of rotavirus-positive cases and...